A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.5K citations

Medicine, Oncology, Pharmacology +14

Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Ying Kuen Cheung, Rick Chappell · Biometrics · 2000 · 534 citations

Medicine, Biostatistics, Oncology +13

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

Birgit Geoerger, Darren Hargrave, Fabienne Thomas et al. · Neuro-Oncology · 2010 · 159 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

Sophie Postel‐Vinay, Laurence Collette, Xavier Paolettí et al. · European Journal of Cancer · 2014 · 122 citations

Medicine, Oncology, Pharmacology +17

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group

P. Schöffski, S. Riggert, P. Fumoleau et al. · Annals of Oncology · 2004 · 80 citations · Full text

Medicine, Oncology, Pharmacology +10